Neutrophil gelatinase-associated lipocalin is instrumental in the pathogenesis of antibody-mediated nephritis in mice

Arthritis and Rheumatism

Volumn 64, Issue 5, 2012, Pages 1620-1631

  Pawar, Rahul D ^a   Pitashny, Milena ^a,f   Gindea, Simona ^a   Tieng, Arlene Tan ^a   Levine, Benjamin ^a   Goilav, Beatrice ^a   Campbell, Sean R ^a   Xia, Yumin ^a   Qing, Xiaoping ^a,c   Thomas, David B ^b   Herlitz, Leal ^d   Berger, Thorsten ^e   Mak, Tak W ^e   Putterman, Chaim ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c American International Pathology Laboratories   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 3 INHIBITOR; DNA ANTIBODY; MONOCLONAL ANTIBODY; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN BINDING; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME ACTIVATION; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNE COMPLEX NEPHRITIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; KIDNEY INJURY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; SURVIVAL; URINARY EXCRETION;

ACUTE-PHASE PROTEINS; ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE SILENCING; GLOMERULAR MESANGIUM; KIDNEY; LIPOCALINS; LONGEVITY; LUPUS NEPHRITIS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEPHRITIS; ONCOGENE PROTEINS; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84860479279     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33485     Document Type: Article

References (34)

1. Fu Y, Du Y, Mohan C,. Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis. Clin Immunol 2007; 124: 109-18.
2. Cowland JB, Borregaard N,. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 1997; 45: 17-23.
3. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L,. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 1996; 38: 414-20.
4. Rubinstein T, Pitashny M, Putterman C,. The novel role of neutrophil gelatinase-B associated lipocalin (NGAL)/lipocalin-2 as a biomarker for lupus nephritis. Autoimmun Rev 2008; 7: 229-34.
5. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003; 14: 2534-43.
6. Yang J, Mori K, Li JY, Barasch J,. Iron, lipocalin, and kidney epithelia. Am J Physiol Renal Physiol 2003; 285: F9-18.
7. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005; 115: 610-21.
8. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P,. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004; 24: 307-15.
9. Mishra J, Ma Q, Kelly C, Mitsnefes M, Mori K, Barasch J, et al. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol 2006; 21: 856-63.
10. Trachtman H, Christen E, Cnaan A, Patrick J, Mai V, Mishra J, et al, and Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial. Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr Nephrol 2006; 21: 989-94.
11. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S,. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 2006; 26: 287-92.
12. Hirsch R, Dent C, Pfriem H, Allen J, Beekman RH III, Ma Q, et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 2007; 22: 2089-95.
13. Wagener G, Gubitosa G, Wang S, Borregaard N, Kim M, Lee HT,. Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery. Am J Kidney Dis 2008; 52: 425-33.
14. Di Grande A, Giuffrida C, Carpinteri G, Narbone G, Pirrone G, Di Mauro A, et al. Neutrophil gelatinase-associated lipocalin: a novel biomarker for the early diagnosis of acute kidney injury in the emergency department. Eur Rev Med Pharmacol Sci 2009; 13: 197-200.
15. Qing X, Zavadil J, Crosby MB, Hogarth MP, Hahn BH, Mohan C, et al. Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells. Arthritis Rheum 2006; 54: 2198-210.
16. Pitashny M, Schwartz N, Qing X, Hojaili B, Aranow C, Mackay M, et al. Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum 2007; 56: 1894-903.
17. Rubinstein T, Pitashny M, Levine B, Schwartz N, Schwartzman J, Weinstein E, et al. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) 2010; 49: 960-71.
18. Brunner HI, Mueller M, Rutherford C, Passo MH, Witte D, Grom A, et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2577-84.
19. Hinze CH, Suzuki M, Klein-Gitelman M, Passo MH, Olson J, Singer NG, et al. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum 2009; 60: 2772-81.
20. Suzuki Y, Shirato I, Okumura K, Ravetch JV, Takai T, Tomino Y, et al. Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis. Kidney Int 1998; 54: 1166-74.
21. Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G,. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 1997; 51: 1583-9.
22. Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, et al. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2006; 103: 1834-9.
23. Saiga H, Nishimura J, Kuwata H, Okuyama M, Matsumoto S, Sato S, et al. Lipocalin 2-dependent inhibition of mycobacterial growth in alveolar epithelium. J Immunol 2008; 181: 8521-7.
24. Xie C, Sharma R, Wang H, Zhou XJ, Mohan C,. Strain distribution pattern of susceptibility to immune-mediated nephritis. J Immunol 2004; 172: 5047-55.
25. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, et al. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2007; 18: 407-13.
26. Devireddy LR, Gazin C, Zhu X, Green MR,. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 2005; 123: 1293-305.
27. Miharada K, Hiroyama T, Sudo K, Nagasawa T, Nakamura Y,. Lipocalin 2 functions as a negative regulator of red blood cell production in an autocrine fashion. FASEB J 2005; 19: 1881-3.
28. Paragas N, Qiu A, Zhang Q, Samstein B, Deng SX, Schmidt-Ott KM, et al. The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat Med 2011; 17: 216-22.
29. Tesch GH, Schwarting A, Kinoshita K, Lan HY, Rollins BJ, Kelley VR,. Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. J Clin Invest 1999; 103: 73-80.
30. Shinozaki M, Hirahashi J, Lebedeva T, Liew FY, Salant DJ, Maron R, et al. IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis. J Clin Invest 2002; 109: 951-60.
31. Niranjan T, Murea M, Susztak K,. The pathogenic role of Notch activation in podocytes. Nephron Exp Nephrol 2009; 111: e73-9.
32. Menke J, Zeller GC, Kikawada E, Means TK, Huang XR, Lan HY, et al. CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease. J Am Soc Nephrol 2008; 19: 1177-89.
33. Panzer U, Steinmetz OM, Reinking RR, Meyer TN, Fehr S, Schneider A, et al. Compartment-specific expression and function of the chemokine IP-10/CXCL10 in a model of renal endothelial microvascular injury. J Am Soc Nephrol 2006; 17: 454-64.
34. Viau A, El Karoui K, Laouari D, Burtin M, Nguyen C, Mori K, et al. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest 2010; 120: 4065-76.